Table 3.
Demographic and outcomes data, grouped by pre-treatment expression of pIGF-1R, as assessed by immunocytochemistry.
| IHC pIGF-1R Status | ||||
|---|---|---|---|---|
| Gender | pIGF-1R Negative | pIGF-1R Positive | All | |
| Female | 2 | 3 | 5 | |
| Male | 4 | 9 | 13 | |
| All | 6 | 12 | 18 | |
| Age at Diagnosis | Mean | 20.8 | 22.6 | 22 |
| Median | 22.5 | 21 | 21 | |
| Min | 10.2 | 12.3 | 10.2 | |
| Max | 31.3 | 46.8 | 46.8 | |
| Tissue Type | ||||
| Bone | 5 | 12 | 17 | |
| Soft tissue | 1 | 0 | 1 | |
| All | 6 | 12 | 18 | |
| PFS | Mean | 12.7 | 4.88 | 7.48 |
| Median | 9.7 | 1.45 | 3.65 | |
| OS | Mean | 46.2 | 20.2 | 28.9 |
| Median | 47.3 | 6.5 | 16.8 | |
| IGF-1R best response | ||||
| Progression | 0 | 7 | 7 | |
| Stable Disease | 0 | 1 | 1 | |
| Partial response | 5 | 4 | 9 | |
| Complete Response | 1 | 0 | 1 | |
| All | 6 | 12 | 18 | |
| Clinical Benefit | ||||
| Progression | 0 | 7 | 7 | |
| Benefit | 6 | 5 | 11 | |
| All | 6 | 12 | 18 | |
| Week 6 Response (WHO) | Mean | 39.3 | 114 | 88.9 |
| Median | 25.4 | 120 | 76.9 | |
| Week 6 Response (RECIST) | Mean | 66.2 | 93.4 | 84.4 |
| Median | 63.5 | 105 | 84 | |
| Week 6 Response (SUV-Max) | Mean | 62.2 | 108 | 98.6 |
| Median | 62.2 | 102 | 74.8 | |
| Week 6 Response (SUV-Peak) | Mean | 46.4 | 106 | 94.1 |
| Median | 46.4 | 99.9 | 77.6 | |
| Biomarker (WHO Percent) | Mean | 67.5 | 102 | 89.7 |
| Median | 65.9 | 91 | 81.8 | |
| Biomarker (RECIST Percent) | Mean | 86.1 | 96.9 | 93 |
| Median | 86.9 | 100 | 98.4 | |
Week-6 response measures indicate the tumor size at 6-weeks, expressed as a percentage of the baseline tumor parameters set at 100%. Biomarker WHO and RECIST percentages, similarly, indicate the size of the tumors obtained during the early day 9–14 PET/CTs compared the baseline tumor measurements. Values less than 100% indicate tumors that are smaller than their baseline pretreatment assessment, whereas values greater than 100% are indicative of tumor growth.